Shareholders Approve New Equity Incentive Plan Authorizing 350K Shares, Plus Annual 5% Evergreen Provision

summarizeSummary

Ernexa Therapeutics shareholders approved a new equity incentive plan, reserving 350,000 shares and including an annual 5% evergreen provision, which could lead to significant dilution for existing shareholders.

check_boxKey Events · Financing and Capital Events · ERNA

• Equity Incentive Plan Approved

  Shareholders approved the 2026 Omnibus Equity Incentive Plan at the Annual Meeting held on July 1, 2026. This follows a DEF 14A filing on May 11, 2026, which proposed the plan.

• Significant Initial Share Reserve

  The plan initially reserves 350,000 shares for awards. Based on 1,166,333 shares outstanding as of May 6, 2026 (post-reverse split), this represents a potential dilution of approximately 30%.

• Annual Evergreen Provision

  The plan includes an evergreen provision, automatically increasing the share reserve by 5% of outstanding common stock each January 1st from 2027 through 2036, adding to long-term dilutive potential.

• Routine Annual Meeting Outcomes

  Shareholders also elected five directors and ratified Haskell & White LLP as the independent registered public accounting firm for 2026.

auto_awesomeAnalysis · ERNA · Life Sciences

Shareholders approved the 2026 Omnibus Equity Incentive Plan, which initially reserves 350,000 shares for awards. This represents a significant potential dilution of approximately 30% based on the 1,166,333 shares outstanding as of May 6, 2026. Furthermore, the plan includes an 'evergreen' provision that will automatically increase the share reserve by 5% of outstanding common stock annually for the next decade. While equity incentive plans are standard for attracting and retaining talent, this level of potential dilution is substantial for a micro-cap company facing ongoing going concern doubts, as noted in previous financial filings.